Elanco Animal Health (NYSE:ELAN) Issues FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.800-0.860 for the period, compared to the consensus estimate of 0.830. The company issued revenue guidance of $4.5 billion-$4.6 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its Q2 2025 guidance to 0.170-0.210 EPS.

Analyst Ratings Changes

Several research firms have issued reports on ELAN. Piper Sandler dropped their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Morgan Stanley reduced their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus upped their price target on Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday. UBS Group decreased their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Finally, Barclays decreased their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $15.00.

Elanco Animal Health Price Performance

NYSE:ELAN traded up $0.89 during mid-day trading on Monday, reaching $12.85. The stock had a trading volume of 3,580,606 shares, compared to its average volume of 4,982,134. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a one year low of $8.02 and a one year high of $18.80. The firm has a 50 day moving average price of $9.89 and a two-hundred day moving average price of $11.42. The stock has a market capitalization of $6.38 billion, a P/E ratio of 32.11, a P/E/G ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. During the same period in the prior year, the firm earned $0.34 earnings per share. The firm's revenue for the quarter was down 1.0% on a year-over-year basis. As a group, analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were bought at an average price of $10.90 per share, with a total value of $109,000.00. Following the purchase, the director now owns 101,459 shares of the company's stock, valued at $1,105,903.10. This trade represents a 10.93% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.89% of the stock is owned by corporate insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.